FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**OMB APPROVAL** 

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

of Section 30(ft) of the investment company Act of 1340												
1. Name and Address Galante Josep	ss of Reporting Perso	n*	2. Issuer Name and Ticker or Trading Symbol  CUMBERLAND PHARMACEUTICALS  INC [ CPIX ]		tionship of Reporting Perso all applicable) Director Officer (give title	10% Owner Other (specify						
(Last) (First) (Middle)  2525 WEST END AVENUE  SUITE 950  (Street)  NASHVILLE TN 37203  (City) (State) (Zip)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/13/2019		below)	below)						
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person								

Tab	ole I - Non-Derivative S	ecurities Acq	uired,	Disp	osed of,	or Ben	eficially	Owned		
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed O 5)	s Acquired f (D) (Instr	I (A) or . 3, 4 and	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	06/13/2019		P		60(1)	A	\$6.42	11,618	D	
Common Stock	06/14/2019		P		60(1)	A	\$6.37	11,678	D	
Common Stock	06/17/2019		P		60(1)	A	\$6.33	11,738	D	
Common Stock	06/18/2019		P		60(1)	A	\$6.36	11,798	D	
Common Stock	06/19/2019		P		60(1)	A	\$6.35	11,858	D	
Common Stock	06/20/2019		P		60(1)	A	\$6.33	11,918	D	
Common Stock	06/21/2019		P		60(1)	A	\$6.34	11,978	D	
Common Stock	06/24/2019		P		60(1)	A	\$6.54	12,038	D	
Common Stock	06/25/2019		P		60(1)	A	\$6.56	12,098	D	
Common Stock	06/26/2019		P		60(1)	A	\$6.54	12,158	D	
Common Stock	06/27/2019		P		60(1)	A	\$6.48	12,218	D	
Common Stock	06/28/2019		P		60(1)	A	\$6.49	12,278	D	
Common Stock	07/01/2019		P		60(1)	A	\$6.52	12,338	D	
Common Stock	07/02/2019		P		60(1)	A	\$6.49	12,398	D	
Common Stock	07/03/2019		P		60(1)	A	\$6.46	12,458	D	
Common Stock	07/05/2019		P		60(1)	A	\$6.49	12,518	D	
Common Stock	07/08/2019		P		60(1)	A	\$6.37	12,578	D	
Common Stock	07/09/2019		P		60(1)	A	\$6.15	12,638	D	
Common Stock	07/10/2019		P		60(1)	A	\$6.07	12,698	D	
Common Stock	07/11/2019		P		60(1)	A	\$5.93	12,758	D	
Common Stock	07/12/2019		P		60(1)	A	\$6.01	12,818	D	
Common Stock	07/15/2019		P		60(1)	A	\$5.85	12,878	D	
Common Stock	07/16/2019		P		60(1)	A	\$5.88	12,938	D	
Common Stock	07/17/2019		P		60(1)	A	\$5.85	12,998	D	
Common Stock	07/18/2019		P		60(1)	A	\$5.84	13,058	D	
Common Stock	07/19/2019		P		60(1)	A	\$5.69	13,118	D	
Common Stock	07/22/2019		P		60(1)	A	\$5.75	13,178	D	
Common Stock	07/24/2019		P		60(1)	A	\$5.93	13,238	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	tle of 2. 3. Transaction 3A. Deemed 4. Active Conversion or Exercise (Month/Day/Year) if any Co		Transa Code (			rative rities ired r osed )	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

### **Explanation of Responses:**

1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.

#### Remarks:

Joseph C. Galante by /s/

Michael Bonner as attorney-in- 07/26/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.